Provided by Tiger Trade Technology Pte. Ltd.

Immutep

4.06
-0.2800-6.45%
Pre-market: 4.330.2700+6.65%05:48 EDT
Volume:10K
Turnover:39.72K
Market Cap:29.88M
PE:-0.54
High:4.31
Open:4.28
Low:4.04
Close:4.34
52wk High:70.60
52wk Low:4.04
Shares:7.36M
Float Shares:6.90M
Volume Ratio:0.45
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.4575
EPS(LYR):-7.4576
ROE:-77.31%
ROA:-42.45%
PB:0.70
PE(LYR):-0.54

Loading ...

Immutep Details Equity Interests of Departing Director Pete Meyers

TIPRANKS
·
Oct 05

Immutep Reports Lapse of 2 Million Performance Rights

TIPRANKS
·
Oct 05

Immutep Announces Board Resignation and Search for New Non-Executive Director

TIPRANKS
·
Oct 05

Immutep Director Increases Shareholding Through Performance Rights Exercise

TIPRANKS
·
Oct 01

Immutep Applies to Quote New Ordinary Shares on ASX

TIPRANKS
·
Oct 01

Immutep Receives ~A$0.86 Million R&D Tax Incentive

GlobeNewswire
·
Sep 30

Immutep Ltd trading halted, news pending

TIPRANKS
·
Sep 26

NASDAQ Trade Halt Halt News Pending at 07:50 Pm

Reuters
·
Sep 26

Change to American Depositary Share Ratio

GlobeNewswire
·
Sep 21

Immutep Gets a New Bull at Jefferies

Dow Jones
·
Sep 15

Immutep provides update on development strategy for eftilagimod alfa

TIPRANKS
·
Sep 11

Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)

GlobeNewswire
·
Sep 11

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

GlobeNewswire
·
Jul 24

Immutep Granted New US Patent for Cancer Treatment Methods

MT Newswires Live
·
Jul 14

Immutep granted new patent for eftilagimod alfa combination

TIPRANKS
·
Jul 14

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

GlobeNewswire
·
Jul 14

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

GlobeNewswire
·
Jul 13

Immutep Shares Rise After Maxim Group Upgrade

MT Newswires Live
·
Jun 18

Immutep Raised to Buy From Hold by Maxim Group

Dow Jones
·
Jun 17

Maxim Group Upgrades Immutep to Buy From Hold, $1.50 Price Target

MT Newswires Live
·
Jun 17